<DOC>
	<DOCNO>NCT01894243</DOCNO>
	<brief_summary>This 2-part study patient advance solid tumour . Part A investigate PK olaparib patient mild moderate hepatic impairment compare patient normal hepatic function ; Part B allow patient mild moderate hepatic impairment normal hepatic function continue access olaparib PK phase provide additional safety data .</brief_summary>
	<brief_title>Study Assess Blood Levels Safety Olaparib Patients With Advanced Solid Tumours Normal Liver Function Mild Moderate Liver Impairment</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<criteria>Inclusion criterion : For inclusion study patient hepatic impairment , follow criterion must meet : 1 . Patients must stable mild hepatic impairment ( define ChildPugh classification ) , least 1 month prior start study stable moderate hepatic impairment ( define Child Pugh classification ) least 2 week prior start study . Patients hepatic metastasis and/or HCC eligible study , provide hepatic metastasis HCC sole reason change liver function satisfy criterion mild moderate hepatic impairment define Child Pugh criterion . Patients must globally impair hepatic function participate study . For inclusion study patient normal hepatic function , follow criterion must meet : 2 . Negative result serum hepatitis B surface antigen hepatitis C antibody . 3 . Total bilirubin less equal to1.5 x institutional upper limit normal ( ULN ) , albumin prothrombin time within normal limit must ascites ( unless relate disease study ) encephalopathy . 4 . Aspartate aminotransferase serum glutamic oxaloacetic transaminase ( AST ) , alanine aminotransferase serum glutamic pyruvic transaminase ( ALT ) less equal 2.5 x institutional ULN unless liver metastasis present case must less equal 5 x ULN . All patient must fulfil follow criterion : 5 . Provision write informed consent prior study specific procedure . 6 . Patients must great equal to18 year age . 7 . Histologically , appropriate , cytologically confirm malignant solid tumour refractory resistant standard therapy suitable effective standard therapy exist . In case HCC , histological cytological confirmation require following situation , per international guideline scientific society European Society Medical Oncology ( ESMO ) American Association Study Liver Diseases ( AASLD ) : Nodules &gt; 2 cm typical feature HCC dynamic imaging technique , nodule associate Î±fetoprotein ( AFP ) concentration &gt; 400 ng/ml rise AFP sequential determination , require biopsy consider proven HCC ( Jelic et al 2010 ) . Nodules &gt; 1 cm find ultrasound screen cirrhotic liver investigate either 4phase multidetector CT scan dynamic contrast enhance MRI . If appearance typical HCC ( ie , hypervascular arterial phase washout portal venous delay phase ) , lesion treat HCC . If finding characteristic vascular profile typical , second contrastenhanced study image modality perform , lesion biopsied ( level II ) ( Bruix et al 2011 ) . 8 . Normal organ bone marrow function measure within 28 day prior administration IP define : Haemoglobin great equal 9.0 g/dL , blood transfusion previous 28 day . Absolute neutrophil count ( ANC ) great equal to1.5 x 109/L . White blood cell ( WBC ) great 3 x 109/L . Platelet count great equal 75 x 109/L . Serum creatinine less equal to1.5 x institutional ULN . 9 . Calculated serum creatinine clearance great 50 mL/min ( use CockcroftGault formula 24hour urine collection ) . 10 . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 . 11 . Patients must life expectancy great equal 8 week . 12 . Evidence non childbearing status woman childbearing potential , postmenopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment Day 1 first treatment period Part A. Postmenopausal define : Amenorrheic 1 year follow cessation exogenous hormonal treatment . Luteinising hormone folliclestimulating hormone level postmenopausal range woman 50 year age . Radiationinduced oophorectomy last menses great 1 year ago . Chemotherapyinduced menopause great 1 year interval since last menses . Surgical sterilisation ( bilateral oophorectomy hysterectomy ) . 13 . Patients willing able comply protocol duration study include undergoing treatment schedule visit examination . 14 . Patients must stable concomitant medication regimen ( exception electrolyte supplement ) , define change medication dose within 2 week prior start olaparib dose , except bisphosphonates , denosumab corticosteroid , stable least 4 week prior start olaparib dosing . Exclusion criterion : 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff , agent and/or staff study site ) . 2 . Previous enrolment present study . 3 . Treatment investigational product ( IP ) last 14 day ( long period depend defined characteristic agent use ) . 4 . Treatment previous 3 month dose study drug know well define potential hepatoxicity ( eg , halothane ) . 5 . Patients receive systemic chemotherapy radiotherapy ( except palliative reason ) within 2 week prior study treatment . The patient receive stable dose bisphosphonates denosumab bone metastasis study long start least 4 week prior treatment . 6 . Patients receive receive inhibitor inducer CYP3A4 within washout period . 7 . Toxicities ( great equal CTCAE Grade 2 ) cause previous cancer therapy , exclude alopecia . 8 . Patients symptomatic uncontrolled brain metastasis . A scan confirm absence brain metastasis require . Patients asymptomatic brain metastasis symptomatic stable brain metastasis receive stable dose corticosteroid study long start least 4 week prior treatment . 9 . Major surgery within 2 week start study treatment patient must recover effect major surgery . 10 . Patients consider poor medical risk due serious uncontrolled medical disorder , non malignant systemic disease , uncontrolled seizure , active uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 3 month ) myocardial infarction , uncontrolled major seizure disorder , unstable spinal cord compression , superior vena cava syndrome , extensive bilateral interstitial lung disease high resolution computer tomography ( HRCT ) scan , psychiatric disorder prohibits obtain informed consent . 11 . Patients history heart failure leave ventricular dysfunction . 2 . Patients gastric , gastrooesophageal oesophageal cancer . 13 . Patients unable swallow orally administer medication patient gastrointestinal disorder significant gastrointestinal resection likely interfere absorption olaparib . 14 . Breastfeeding woman . 15 . Immunocompromised patient eg , patient know serologically positive human immunodeficiency virus ( HIV ) . 16 . Patients know hypersensitivity olaparib excipients product . 17 . Resting ECG measurable QTc great 470 msec 2 time point within 24 hour period family history long QT syndrome . 18 . Clinical judgment investigator patient participate study . In addition exclusion criterion 1 18 , patient normal hepatic function enter study follow exclusion criterion fulfil : 19 . History presence hepatic disease know interfere absorption , distribution , metabolism excretion olaparib . In addition exclusion criterion 1 18 , patient mild moderate hepatic impairment enter study follow exclusion criterion fulfil : 20 . Patients hepatic encephalopathy ( described Child Pugh Classification system ) . 21 . Fluctuating rapidly deteriorate hepatic function indicate widely vary worsen clinical and/or laboratory sign hepatic impairment within screen period ( eg , advanced ascites , fever , active gastrointestinal bleeding ) . 22 . Change dose regimen medically require medication within last 2 week screen and/or use disallow comedication 3 week prior admission clinic . 23 . Presence acute liver disease cause drug toxicity infection . 24 . Severe portal hypertension surgical portosystemic shunt . 25 . Biliary obstruction cause hepatic impairment relate parenchymal disorder and/or disease liver . 26 . Oesophageal variceal bleeding within past 2 month . 27 . Anticoagulant therapy warfarin related coumarins .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>oncology ,</keyword>
	<keyword>cancer ,</keyword>
	<keyword>neoplasm ,</keyword>
	<keyword>anticancer drug ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>area curve ,</keyword>
	<keyword>olaparib ,</keyword>
	<keyword>solid tumour ,</keyword>
	<keyword>mild hepatic impairment ,</keyword>
	<keyword>moderate hepatic impairment</keyword>
</DOC>